Deadline(s) (LOI if required)	Sponsor	Program	Description	Eligibility/Requirements	Amount (max, if range)	Grant term	Contact email	Contact name (if available)
Application opens: 8/1/2023 Full Application due: 12/5/2023	**American Gastroenterological Association**	AGA-Bristol Myers Squibb Research Scholar Award in Inflammatory Bowel Disease	This award provides support to early-career faculty (i.e., instructor, assistant professor) working toward an independent career in inflammatory bowel disease (IBD) research	Applicants must classify as early-career; must hold an MD, PhD and/or equivalent degree (e.g., MBChB, MBBS, DO), and a full-time faculty or equivalent position at an institution in North America (US, Canada or Mexico) by the start date (i.e., July 2024) of this award. Applicants who are physician-scientists, female or from racial/ethnic groups underrepresented in biomedical research are strongly encouraged to apply	$300,000	3 years	awards@gastro.org	
LOI due: 8/31/2023 Full Application due: 11/1/2023	**Burroughs Wellcome Fund**	Climate and Health Interdisciplinary Awards	The Burroughs Wellcome Fund Climate and Health Interdisciplinary Award provides support for collaborative exploratory work that opens new ground for comprehensively assessing or mitigating the impacts of climate change on human health. This program will support both individual scientists and multi-investigator teams. Early-career faculty and postdoctoral fellows nearing their transition to independence are especially encouraged to apply, whether individually or within teams	Postdoctoral fellows and early-career faculty are eligible.	375000	3 years	vmcgovern@bwfund.org; dlewandowski@bwfund.org	Victoria McGovern; Darcy Lewandowski
Letter of Intent due: N/A Annual Application due: 9/27/2023	**Department of Army**	Peer Reviewed Cancer, Translational Team Science Award	This award supports hypothesis-driven translational studies. These studies must be associated with ongoing or completed clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations and to utilize information from the clinical trials for research that would then inform the clinic. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings. The TTSA is not intended to support high-throughput screenings or sequencing. The goal of the TTSA is to bring together a synergistic team of investigators to address clinical problems that may have an impact on patient outcomes.	The investigator(s) named as the Partnering PI(s) on the application must be at or above the level of Assistant Professor or equivalent. Postdoctoral fellows are not eligible to be Initiating or Partnering PIs. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.	36000000			
Letter of Intent due: N/A Annual Application due: Cycle III: 10/5/2023	**National Institutes of Health**	Impacts of Climate Change Across the Cancer Control Continuum (R01 Clinical Trial Optional)	This notice of funding opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	curt.dellavalle@nih.gov	Curt DellaValle PhD, MPH
Letter of Intent due: N/A Annual Application due: Cycle III: 10/13/2023	**National Institutes of Health**	Impacts of Climate Change Across the Cancer Control Continuum (R21 Clinical Trial Optional)	This Notice of Funding Opportunity (NOFO) aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. This includes, but is not limited to, studies to improve knowledge of the impact of climate change related environmental effects on cancer risks, control and behaviors.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	275000	2 years	curt.dellavalle@nih.gov	Curt DellaValle PhD, MPH
Letter of Intent due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)	This funding opportunity announcement (NOFO) invites research grant applications that propose the development and evaluation of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain and the incorporation of pilot or clinical feasibility evaluation from previously collected data in pre-clinical studies. These studies are expected to provide the requisite data needed to advance promising PET ligands for use in clinical research. Projects proposing only preclinical animal studies should consider the companion NOFO (PAR-23-164).	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Application budgets are not limited but need to reflect the actual needs of the proposed project.	5 years	heather.weiss@nih.gov	Heather Weiss
Letter of Intent due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)	The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Application budgets are not limited but need to reflect the actual needs of the proposed scientific research project and DEIA activities.	5 years	rosenzwj@nigms.nih.gov	Justin Rosenzweig
Letter of Intent due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)	The NIH Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Application budgets are not limited but need to reflect the actual needs of the proposed scientific research project and DEIA activities.	5 years	rosenzwj@nigms.nih.gov	Justin Rosenzweig

Letter of Intent due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)	The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to: (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. The overall goal is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Application budgets are not limited but need to reflect the actual needs of the proposed project.	5 years	margaret.young@nih.gov	Margaret Young
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, et al**	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This funding opportunity announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	5 years	amy.bartosch@nih.gov	Amy Bartosch
Letter of Intent due: 30 days before due date Application due: 10/10/2023	**National Institutes of Health, et al**	Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)	This initiative will support intervention research that addresses structural racism and discrimination (SRD) in order to improve minority health or reduce health disparities.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.	500000	5 years	pg38h@nih.gov	Priscilla Grant JD
Letter of Intent due: N/A Application due: Cycle III: 10/16/2023	**National Institutes of Health, et al**	Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)	The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to this data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	200000	2 years	margaret.young@nih.gov	Margaret Young
Letter of Intent due: 60 days before due date Application due: 10/13/2023	**National Institutes of Health, et al**	Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)	This funding opportunity announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Award budgets are composed of salary and other program-related expenses	5 years	crystal.wolfrey@nih.gov	Crystal Wolfrey
Letter of Intent due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)	This funding opportunity announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function, and aging in healthy and disease states. This FOA is intended to encourage the further development of projects with feasibility support for the line of investigation. Applicants proposing exploratory research at the early and conceptual stages of project development may instead wish to apply to the companion R21 FOA (PAR-23-047).	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	heather.weiss@nih.gov	Heather Weiss
Letter of Intent due: 30 days before due date Application due: 11/22/2023	**National Institutes of Health, et al**	The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)	The purpose of this funding opportunity announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Women's Health (ORWH) and the scientific partnering Institutes and Centers across NIH.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	350000	4 years	e.melvin@nih.gov	E.C. Melvin

Letter of Intent due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)	The purpose of this funding opportunity announcement (FOA) is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	shane.woodward@nih.gov	Shane Woodward
Letter of Intent due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)	The purpose of this funding opportunity announcement is to encourage collaborations- between life science and physical science- that: 1) apply a multidisciplinary bioengineering approach to solve biomedical problems; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or; c) improve practice of medicine. Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	shane.woodward@nih.gov	Shane Woodward
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)	This funding opportunity announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial must apply to the "Independent Clinical Trial Not Allowed companion FOA (PAR-21-128).	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	3 years	amy.bartosch@nih.gov	Amy Bartosch
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed)	This funding opportunity announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) and who has at least 2 years of postdoctoral cancer research training, but, no more than a total of 8 years of mentored, non-independent training experience after the terminal research doctorate or clinical degree is invited to work with his/her organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	3 years	amy.bartosch@nih.gov	Amy Bartosch
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)	This funding opportunity announcement (FOA) is a continuation of the NCI Mentored Research Scientist Development Award to Promote Diversity (K01) to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible individuals from diverse backgrounds, including groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.	Any candidate who meets the eligibility and possesses the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	5 years	hines@mail.nih.gov	Sean Hine
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed)	This funding opportunity announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position. This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) and who has at least 2 years of postdoctoral cancer research training, but, no more than a total of 8 years of mentored, non-independent training experience after the terminal research doctorate or clinical degree is invited to work with his/her organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	3 years	amy.bartosch@nih.gov	Amy Bartosch

Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)	This funding opportunity announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) and who has at least 2 years of postdoctoral cancer research training, but, no more than a total of 8 years of mentored, non-independent training experience after the terminal research doctorate or clinical degree is invited to work with his/her organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	3 years	amy.bartosch@nih.gov	Amy Bartosch
Letter of Intent due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, National Cancer Institute**	Co-infection and Cancer (R01 Clinical Trial Not Allowed)	The purpose of this funding opportunity announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
Letter of Intent due: N/A Application due: Cycle III: 10/17/2023	**National Institutes of Health, National Cancer Institute**	NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)	This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	50000	2 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
Letter of Intent due: 30 days before due date Application due: 10/16/2023	**National Institutes of Health, National Cancer Institute, National Institute on Drug Abuse**	Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required)	The purpose of this funding opportunity announcement (FOA) is to support studies that develop, test, implement, and evaluate behavioral tobacco cessation interventions for adolescents, with a focus on the critical developmental risk period of mid- to late adolescence (approximately 14-20 years old).	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	3150000	5 years	dm437a@nih.gov	Dawn Mitchum
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Institute of Allergy and Infectious Diseases**	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required)	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This funding opportunity announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. K99/R00 candidates must have no more than 4 years of total aggregate postdoctoral research experience as of the relevant application due date regardless of whether it is a new, revision, or resubmission application. Individuals must be in mentored, postdoctoral training positions to be eligible to apply to the K99/R00 program (i.e., eligible candidates include residents, clinical fellows, instructors, and clinical assistant professors). If a candidate achieves independence (i.e., any faculty or non-mentored research position) before a K99 award is made, neither the K99 award, nor the R00 award, will be issued	Award budgets are composed of salary and other program-related expenses	4 years	kalaya.goffigan@nih.gov	Kalaya Goffigan
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Institute of Allergy and Infectious Diseases**	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This funding opportunity announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	4 years	kalaya.goffigan@nih.gov	Kalaya Goffigan
Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Institute of Allergy and Infectious Diseases**	NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed)	The purpose of the NIAID Physician-Scientist Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented independent physician-scientists. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. Multiple PDs/PIs are not allowed. K99/R00 candidates must have no more than 4 years of total aggregate postdoctoral research experience as of the relevant application due date regardless of whether it is a new, revision, or resubmission application. Individuals must be in mentored, postdoctoral training positions to be eligible to apply to the K99/R00 program (i.e., eligible candidates include residents, clinical fellows, instructors, and clinical assistant professors). If a candidate achieves independence (i.e., any faculty or non-mentored research position) before a K99 award is made, neither the K99 award, nor the R00 award, will be issued. Applicants must complete a minimum of 12 months of mentored research training and career development (K99 phase) to be eligible for transition to	Award budgets are composed of salary and other program-related expenses	4 years	kalaya.goffigan@nih.gov	Kalaya Goffigan

Letter of Intent due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Institute on Aging**	Mentored Career Development Program for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed)	The purpose of this funding opportunity announcement (FOA) is to provide early-stage investigators with support and "protected time" (up to five years) for intensive, research-focused career development program activities under the guidance of an experienced mentorship team with expertise in both the preclinical application of nonhuman primate (NHP) models and in translation of the results from such studies to clinical application. The focus of this program is to increase the number of highly skilled scientists using NHP models to address complex translational biomedical research designed to foster translation of outcomes into the clinic. The expectation is that through this sustained period of research career development and training, awardees will launch independent research careers and become competitive for new research project grant (e.g., R01) funding. This funding opportunity announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	5 years	kalaya.goffigan@nih.gov	Kalaya Goffigan
Letter of Intent due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, National Institute of Mental Health**	Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)	The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition (or perimenopause). In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the acutual needs of the proposed budget	5 years	siscor@mail.nih.gov	Rita Sisco
Letter of Intent due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, National Institute on Aging**	Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)	The purpose of this funding opportunity announcement (FOA) is to: 1) invite applications that propose to develop and implement early to late stage clinical trials of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and; 2) stimulate studies to enhance trial design and methods.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	jennifer.edwards@nih.gov	Jennifer Edwards
Letter of Intent due: N/A Application due: Cycle III: 10/17/2023	**National Institutes of Health, National Institute on Aging**	NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required)	This funding opportunity announcement (FOA) invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the NIA website.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	philip.smith2@nih.gov	Philip Smith
Letter of Intent due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, National Institutes of Mental Health**	Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01 Clinical Trial Required)	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and test the navigator model's ability to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and test components of navigator models that drive improvements in mental health care; detect and interrogate tailoring variables that optimize the 'personalized match' between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	500000	4 years	tkees@mail.nih.gov	Tamara Kees
Letter of Intent due: N/A Application due: 10/13/2023	**National Institutes of Health; NHLBI, NIA, NIAID, NCI**	Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)	The purpose of the Stimulating Access to Research in Residency Transition Scholar (StARRTS) K38 Career Development program is to retain and support clinician investigators who have successfully completed the Stimulating Access to Research in Residency (StARR) R38 Program (RFA-HL-18-023 or RFA-HL-23-006) as resident-investigators. Individuals who are awarded K38 grants described in this FOA will be referred to as Transition Scholars. The intent of this FOA is to provide Transition Scholars with opportunities for additional research and career development during subsequent clinical fellowship or early career faculty appointments (as defined in Section III. 3. Additional Information on Eligibility). It is anticipated that the StARRTS K38 program will provide a pathway to retain the newly-created pool of clinician-investigators generated through the StARR R38 program. Transition Scholar grantees will receive support for continued research and career development opportunities in basic, clinical and/or translational research thereby providing enhanced potential to accelerate the transition to independent research careers.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	2 years	amy.bartosch@nih.gov	Amy Bartosch
LOI due: N/A Full Application due: Cycle II: 10/2/2023	**Rheumatology Research Foundation**	Career Development Bridge Funding Award: R Bridge	The NIH K Series and VA CDA awards provide limited resources to cover research costs, such as essential laboratory supplies or support staff (e.g., salary support for a research technician, database assistant or statistician), which are crucial to the successful transition of junior investigators to independent investigators. This award is designed to address the needs of these investigators and serve as a supplement to the NIH individual K series, VA CDA, or equivalent 4- or 5- year award mechanism.	Applicants must be a member of the American College of Rheumatology (ACR) or Association of Rheumatology Professionals (ARP) with an MD, DO, PhD or equivalent doctoral level degree from an accredited institution.	$50,000/year	2 years	foundation@rheumatology.org	

LOI due: Fourth Quarter - Nov. 1 (If LOI approved, full proposal due within one year of approval date)	**SENS Research Foundation**	SENS Research Foundation Research Grant (Q2 LOI Submission)	SENS Research Foundation funds external research with potential to accelerate the development of rejuvenation biotechnology.				foundation@sens.org	
Full Application due: 12/16/2023	**Simons Foundation**	SCPAB Transition to Independence Award	The Simons Collaboration on Plasticity and the Aging Brain (SCPAB) Transition to Independence (TTI) Award aims to facilitate the transition of the next generation of outstanding scientists from historically underrepresented groups to research independence in the field of cognitive aging. Candidates with a background in fields including neuroscience, molecular biology, genetics, immunology, cell biology and the physical and information sciences are encouraged to apply.	The request for applications (RFA) is aimed at PhD and MD-holding scientists who are currently in training positions but intend to seek tenure-track research faculty positions during the upcoming academic job cycle	600000	3 years	neurogrants@simonsfoundation.org	
Full Application due: 12/16/2023	**Simons Foundation**	SCGB Transition to Independence Award	The Simons Collaboration on the Global Brain (SCGB) is dedicated to supporting advances in systems and computational neuroscience with the goal of expanding our understanding of the brain's internal states. The Transition to Independence (TTI) Award aims to facilitate the transition of outstanding systems and computational neuroscientists from historically underrepresented backgrounds to research independence.	The program is open to individuals who are from gender, racial, ethnic and other groups underrepresented in systems and computational neuroscience, including individuals from disadvantage backgrounds. Applicants must hold a PhD, MD or equivalent degree; must be in non-independent, mentored training positions; must be actively seeking a tenure-track position at an institution of higher education. Applicants are not eligible if they are recipients of other career development awards with similar budgetary scopes.	$600,000	3 years	neurogrants@simonsfoundation.org	
LOI due: N/A Application due: Cycle III: 10/12/2023	**Agency for Healthcare Research and Quality**	AHRQ Patient-Centered Outcomes Research (PCOR) Mentored Clinical Scientist Career Development Award (K08)	The primary purpose of the AHRQ Patient-Centered Outcomes Research (PCOR) Mentored Clinical Investigator Career Development Award (K08) program is to provide support for qualified individuals for an intensive, mentored research career development experience in comparative effectiveness research (CER) methods as applied to patient-centered outcomes research (PCOR).	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor(s) and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for AHRQ support.	Award budgets are composed of salary and other program-related expenses	5 years	galen.gregor@ahrq.hhs.gov	Galen Gregor
LOI due: N/A Application due: Cycle III: 10/12/2023	**Agency for Healthcare Research and Quality; Office of Extramural Research, Education and Priority Populations (OEREP)**	AHRQ Mentored Clinical Scientist Research Career Development Award (K08)	This notice of funding opportunity (NOFO) requests individual Mentored Clinical Scientist Research Career Development (K08) grant applications from applicant organizations. The overall goal of AHRQ-supported career development programs is to help ensure that a diverse pool of highly trained health services researchers is available in adequate numbers and in appropriate research areas to address the mission and priorities of AHRQ.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for AHRQ support. The K08 award is also available to promote research workforce diversity by providing enhanced research career development opportunities. This funding opportunity may support individuals who propose to embark in health services research training. Eligible individuals who have had a hiatus in their research career because of illness or pressing family circumstances may also apply. Candidates for the K08 award must have a clinical doctoral degree. Such degrees include, but are not limited to: MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), and DVM. Individuals with the PhD or other doctoral degree in clinical disciplines such as clinical psychology, nursing, clinical genetics, speech-language pathology, audiology, or rehabilitation are also eligible.	Award budgets are composed of salary and other program-related expenses	5 years	galen.gregor@ahrq.hhs.gov	Galen Gregor
Application due: 12/5/2023	**American Gastroenterological Association**	AGA Research Scholar Award	The objective of the AGA Research Foundation Research Scholar Award (RSA) is to support early-career investigators working toward independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for research (i.e., a minimum of 50 percent effort dedicated to the proposed project). The award will support junior faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research	Applicants for this award must hold an MD, PhD and/or equivalent degree (e.g., MBChB, MBBS, DO), and a full-time faculty or equivalent position at an institution in North America (U.S., Canada or Mexico) by the start date of this award	$300,000	3 years	awards@gastro.org	
Application due: 12/5/2023	**American Gastroenterological Association**	AGA-Bristol Myers Squibb Research Scholar Award in Inflammatory Bowel Disease	The objective of the AGA Research Foundation Research Scholar Award (RSA) is to support early-career investigators working toward independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for research (i.e., a minimum of 50 percent effort dedicated to the proposed project). This award will support junior faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research pertaining to inflammatory bowel disease	Applicants for this award must hold an MD, PhD and/or equivalent degree (e.g., MBChB, MBBS, DO), and a full-time faculty or equivalent position at an institution in North America (U.S., Canada or Mexico) by the start date of this award	$300,000	3 years	awards@gastro.org	
Application due: 11/15/2023	**Burroughs Wellcome Fund**	Investigators in the Pathogenesis of Infectious Disease	The Investigators in the Pathogenesis of Infectious Disease (PATH) program provides opportunities for assistant professors to bring multidisciplinary approaches to the study of human infectious diseases. The goal of the program is to provide opportunities for accomplished investigators at the assistant professor level to study what happens at the points where the systems of humans and potentially infectious agents connect. The program supports research that sheds light on the fundamentals that affect the outcomes of these encounters: how colonization, infection, commensalism, and other relationships play out at levels ranging from molecular interactions to systemic ones	The ideal candidate is an accomplished investigator at the mid-to-late assistant professor level with an established record of independent research in a tenure-track position or its well-supported equivalent in non-tenure offering departments	$500,000	5 years	dlewandowski@bwfund.org	Darcy Lewandowski
LOI due: 30 days before due date Application due: 10/16/2023	**National Institutes of Health, et al**	Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required)	The purpose of this funding opportunity announcement is to support studies that develop, test, implement and evaluate behavioral tobacco cessation interventions for adolescents, with a focus on the critical developmental risk period of mid-to late adolescence	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Direct costs in any single year should reflect the actual needs of the proposed project; however, total direct costs are limited to $3,150,000 across a 5-yr project period.	5 years	dm437a@nih.gov	Dawn Mitchum
LOI due: N/A Application due: Cycle III: 10/13/2023	**National Institutes of Health, et al**	BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)	The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Award budgets are comprised of salary and other program-related expenses	5 years	tjarosik@mail.nih.gov	Terri Jarosik

LOI due: N/A Application due: Cycle III: 10/13/2023	**National Institutes of Health, et al**	BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)	The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds, including those from underrepresented groups in the biomedical and behavioral sciences, in BRAIN Initiative research areas	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Award budgets are comprised of salary and other program-related expenses	5 years	tjarosik@mail.nih.gov	Terri Jarosik
LOI due: 30 days before due date Application due: Cycle III: 10/13/2023	**National Institutes of Health, et al**	BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)	This notice of funding opportunity solicits applications to develop informatics tools for analyzing, visualizing and integrating data related to BRAIN Initiative or to enhance our understanding of the brain.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	3 years	tkees@mail.nih.gov	Tamara Kees
LOI due: 60 days before due date Application due: 10/27/2023	**National Institutes of Health, et al**	BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)	This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS)	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	3 years	chiefgrantsmanagementofficer@ninds.nih.gov	
LOI due: 30 days before due date Application due: 10/11/2023	**National Institutes of Health, et al**	BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)	This funding opportunity is intended to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. This FOA encourages research project grant applications from multi-disciplinary teams focused on key ethical issues associated with BRAIN Initiative supported research areas.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$300,000	4 years	weissh@mail.nih.gov	Heather Weiss
LOI due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)	This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$500,000	5 years	grantp@mail.nih.gov	Priscilla Grant
LOI due: N/A Application due: 12/7/2023	**National Institutes of Health, et al**	Development of the Fetal Immune System (R01 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to understand the contribution of specific elements of maternal molecular and cellular factors that can control and effect the development of the fetal immune system.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$300,000/year	3 years	clarkb1@mail.nih.gov	Bryan Clark
LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have, in hand, the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIDA, NEI, and/or NIA and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the needs of the proposed project	4 years	tkees@mail.nih.gov	Tamara Kees
LOI due: 30 days before due date Application due: Cycle III: 10/16/2023	**National Institutes of Health, et al**	Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support	$50,000	2 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)	This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	weissh@mail.nih.gov	Heather Weiss
LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)	The purpose of this Funding Opportunity Announcement is to support research that investigates the effectiveness of school-based health centers (SBHCs) as a health services care delivery model to address the needs of school-aged children from populations with health disparities (hence, underserved youth).	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	grantp@mail.nih.gov	Priscilla Grant

LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Engineering Next-Generation Human Nervous System Micophysiological Systems (R01 Clinical Trials Not Allowed)	**This funding opportunity announcement encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy disease states**	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	heather.weiss@nih.gov	Heather Weiss
LOI due: N/A Application due: Cycle III: 11/17/2023	**National Institutes of Health, et al**	Ethical, Legal and Social Implications (ELSI) (Research R01 Clinical Trial Optional)	This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	deanna.ingersoll@nih.gov	Deanna Ingersoll
LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Focused Technology Research and Development (R01 Clinical Trial Not Allowed)	The goal of this FOA is to support the development of technologies with demonstrated proof-of-concept that have remaining significant technical challenges to full implementation and broad utility. As such, applications should not propose to test specific biological questions. Applications proposing to test specific biological questions are not responsive to this FOA and will be administratively withdrawn without review. Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but must reflect the actual needs of the proposed project.	5 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: N/A Application due: Cycle III: 10/12/2023; 2024 Cycle I: 2/12/2024 Cycle II: 6/12/2024 Cycle III: 10/12/2024	**National Institutes of Health, et al**	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)	**The purpose of this Mentored Research Scientist Development Award in Implementation Science for Substance Use Prevention and Treatment (K01) is to provide support and "protected time" (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization. This Funding Opportunity Announcement (FOA) will support early career investigators who have foundational training in substance use prevention or treatment research and will provide support and protected time to acquire training and research experience in implementation science.**	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Candidates for the K01 award must have a research or health-professional doctoral degree. Candidates must demonstrate – via biosketch (degree, training, work experience), publications, and/or reference letters – foundational training or experience in substance use prevention or treatment.	Award budgets are composed of salary and other program-related expenses	5 years	aldersoc@mail.nih.gov	Carol Alderson
LOI due: N/A Application due: Cycle III: 10/12/2023; 2024 Cycle I: 2/12/2024 Cycle II: 6/12/2024 Cycle III: 10/12/2024	**National Institutes of Health, et al**	HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)	The purpose of this Mentored Patient-Oriented Research Career Development Award in Implementation Science for Substance Use Prevention and Treatment (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research from an implementation science perspective. These awards provide salary and research support for a sustained period of "protected time" (3-5 years) for an intensive, supervised career development experience leading to research independence in this area of specialization.	knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. The aggregate total of NIH mentored career award support (both institutional [e.g., KL2, K12] and individual) cannot exceed 6 years. For NIMH applicants, eligibility for the K23 is limited to individuals with no more than 6 years of postdoctoral experience at the time of application (either the initial or resubmission application). Candidates must demonstrate – via biosketch (degree, training, work experience), publications, and/or reference letters – foundational clinical training or experience in substance use prevention or treatment. Current and former PDs/PIs on NIH research project (R01), program project (P01), center grants (P50), Project Leads of program project (P01), or center grants (P50), other major individual career development awards (e.g., K01, K07, K08, K22, K23, K25, K76, K99/R00), or the equivalent are not eligible. Current and former PDs/PIs of an NIH Small Grant (R03), Exploratory/Developmental Grants	Award budgets are composed of salary and other program-related expenses	5 years	aldersoc@mail.nih.gov	Carol Alderson
LOI due: 30 days before due date Application due: Cycle III: 11/7/2023	**National Institutes of Health, et al**	HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed)	This funding opportunity announcement (FOA) invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that will significantly advance translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions with little or no addiction liability	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets need to reflect the actual needs of the proposed project and are limited to direct costs of $750,000 per year.	5 years	chiefgrantsmanagementofficer@ninds.nih.gov	Shellie Wilburn
LOI due: 30 days before due date Application due: Cycle III: 10/4/2023	**National Institutes of Health, et al**	HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	hines@mail.nih.gov	Sean Hine

LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, et al**	Health Care Models for Persons with Multiple Chronic Conditions from Populations that Experience Health Disparities: Advancing Health Care Towards Equity	This initiative will support innovative, collaborative, and multi-disciplinary research designed to study the effective adaptation, integration, and implementation of recommended guidelines of care of persons with multiple chronic conditions (MCCs) from populations that experience health disparities. Projects would be expected to involve more than one component and/or more than one level of influence within existing or newly proposed health care models. The goal of this initiative is attainment of optimal treatment and health outcomes goals to advance health care towards health equity.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 30 days before due date **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, et al**	Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)	The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledge base of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowed).	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited, but need to reflect the actual needs of the proposed project	5 years	amy.bartosch@nih.gov	Amy Bartosch
LOI due: N/A **Application due:** **Cycle III: 10/12/2023**	**National Institutes of Health, et al**	Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)	The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Award budgets are composed of salary and other program-related expenses	5 years	jessi.perez@nih.gov	Jessi Perez
LOI due: N/A **Application due:** **Cycle III: 10/12/2023**	**National Institutes of Health, et al**	Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)	The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Award budgets are composed of salary and other program-related expenses	5 years	jessi.perez@nih.gov	Jessi Perez
LOI due: N/A **Application due:** **10/5/2023**	**National Institutes of Health, et al**	Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)	The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this RO1 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, et al**	Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional)	This funding opportunity announcement (FOA) seeks to support research that examines the impact of leveraging health information technology (health IT) to reduce disparities in access to and utilization of health care services, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	grantp@mail.nih.gov	Priscilla Grant
LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, et al**	Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional)	The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters on health care systems serving health disparity populations in communities in the U.S., including the U.S. territories. NIH-designated health disparity populations include racial and ethnic minorities (Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asians, Native Hawaiians and other Pacific Islanders), sexual and gender minorities, socioeconomically disadvantaged populations, and underserved rural populations.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	pg38h@nih.gov	Priscilla Grant
LOI due: N/A **Application due:** **Cycle III: 10/12/2023**	**National Institutes of Health, et al**	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required)	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Candidates for the K08 award must have a clinical doctoral degree. Such degrees include, but are not limited to: MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), and DVM. Individuals with the PhD or other doctoral degree in clinical disciplines such as clinical psychology, nursing, clinical genetics, speech-language pathology, audiology or rehabilitation are also eligible. Individuals holding the PhD in a non-clinical discipline who are certified to perform clinical duties should contact the appropriate Institute concerning their eligibility for a K08 award.	Award budgets are composed of salary and other program-related expenses	5 years	karen.robinson.smith@nei.nih.gov	Karen Robinson Smith

LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, et al**	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Candidates for the K08 award must have a clinical doctoral degree. Such degrees include, but are not limited to: MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), and DVM. Individuals with the PhD or other doctoral degree in clinical disciplines such as clinical psychology, nursing, clinical genetics, speech-language pathology, audiology or rehabilitation are also eligible. Individuals holding the PhD in a non-clinical discipline who are certified to perform clinical duties should contact the appropriate Institute concerning their eligibility for a K08 award.	Award budgets are composed of salary and other program-related expenses	5 years	karen.robinson.smith@nei.nih.gov	Karen Robinson Smith
LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, et al**	Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)	The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Award budgets are composed of salary and other program-related expenses	5 years	karen.robinson.smith@nei.nih.gov	Karen Robinson Smith
LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, et al**	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Current and former PDs/PIs on NIH research project (R01), program project (P01), center grants (P50), or Project Leads of program project (P01) or center grant (P50) sub-projects, or other major individual career development awards (e.g., K01, K07, K08, K22, K23, K25, K76, K99/R00), or the equivalent are not eligible. Current and former PDs/PIs of an NIH Small Grant (R03), Exploratory/Developmental Grant (R21), Planning Grant (R34/U34), Dissertation Award (R36), or SBIR/STTR (R41, R42, R43, R44) remain eligible, as do PD/PIs of Transition Scholar (K38) awards and individuals appointed to institutional K programs (K12, KL2). Candidates for the K23 award must have a health-professional doctoral degree. Such degrees include, but are not limited to, the MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), as well as a doctoral degree in nursing research or practice. Individuals with the PhD or other doctoral degree in clinical disciplines	Award budgets are composed of salary and other program-related expenses	5 years	karen.robinson.smith@nei.nih.gov	Karen Robinson Smith
LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, et al**	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Current and former PDs/PIs on NIH research project (R01), program project (P01), center grants (P50), other major individual career development awards (e.g., K01, K07, K08, K22, K23, K25, K76, K99/R00), or Project Leads of program project (P01) or center grant (P50) sub-projects, or the equivalent are not eligible. Current and former PDs/PIs of an NIH Small Grant (R03), Exploratory/Developmental Grant (R21), Planning Grant (R34/U34), Dissertation Award (R36), or SBIR/STTR (R41, R42, R43, R44) remain eligible, as do PD/PIs of Transition Scholar (K38) awards and individuals appointed to institutional K programs (K12, KL2). Candidates for the K23 award must have a health-professional doctoral degree. Such degrees include, but are not limited to, the MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), as well as a doctoral degree in nursing	Award budgets are composed of salary and other program-related expenses	5 years	cobbt@mail.nih.gov	Taryn Cobb
LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, et al**	Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)	The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Current and former PDs/PIs on NIH research project (R01), program project (P01), center grants (P50), other major individual career development awards (e.g., K01, K07, K08, K22, K23, K25, K76, K99/R00), or Project Leads of program project (P01) or center grant (P50) sub-projects, or the equivalent are not eligible. Current and former PDs/PIs of an NIH Small Grant (R03), Exploratory/Developmental Grant (R21), Planning Grant (R34/U34), Dissertation Award (R36), or SBIR/STTR (R41, R42, R43, R44) remain eligible, as do PD/PIs of Transition Scholar (K38) awards and individuals appointed to institutional K programs (K12, KL2). Candidates for the K23 award must have a health-professional doctoral degree. Such degrees include, but are not limited to, the MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), as well as a doctoral degree in nursing research or practice. Individuals with the PhD or other doctoral degree in clinical disciplines	Award budgets are composed of salary and other program-related expenses	5 years	cobbt@mail.nih.gov	Taryn Cobb

LOI due: 30 days before due date Application due: 9/26/2023	**National Institutes of Health, et al**	Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$250,000	5 years	pfleming@nida.nih.gov	Pamela Fleming
LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)	This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate 'Clinical Trials Required' or 'Clinical Trial Optional' FOA.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	karen.robinson.smith@nei.nih.gov	Karen Robinson Smith
LOI due: N/A Application due: Cycle III: 9/26/2023	**National Institutes of Health, et al**	Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Humans Required)	The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 30 days before due date Application due: 11/22/2023	**National Institutes of Health, et al**	The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)	**The purpose of this funding announcement is to invite R01 applications on the influence and intersection of sex and gender in health and disease, including: research applications that examine sex and gender factors and their intersection in understanding health disease**	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	$350,000	4 years	hunterc@mail.nih.gov	Chyren Hunter
LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited, but need to reflect the actual needs of the proposed project	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A 2023 Application due dates: Oct. 10; Nov. 9; Dec. 11	**National Institutes of Health, et al**	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	perryc@mail.nih.gov	Carol Perry
LOI due: 30 days before due date Application due: Cycle III: 10/5/2023	**National Institutes of Health, et al**	Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional)	The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the needs of the proposed project	5 years	brightfr@mail.nih.gov	Rebecca Brightful
LOI due: 60 days before due date Application due: 10/6/2023	**National Institutes of Health, et al**	Tobacco Regulatory Science (R01 Clinical Trial Optional)	The purpose of this funding opportunity is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP)	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	$500,000	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey

LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)	The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. They are expected to plan, design, and validate that the solution will be suitable for end users. Each partnership should include at least one academic and one industrial organization. Each partnership should plan to transition a technology, method, assay, device, and/or system from a demonstration of possibility to a status useful in the chosen setting. Funding may be requested to enhance, adapt, optimize, validate, and otherwise translate technologies that address problems in biology, pathology, risk assessment, diagnosis, treatment, and/or monitoring of disease status.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$499,000	5 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 30 days before due date **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$500,000	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 30 days before due date **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)	Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites R01 grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of these modalities in the characterization of therapy response and/or emergence of treatment resistance.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are limited to less than $500K in direct costs per year and the requested amount in any year needs to reflect the actual needs of the proposed project.	5 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: N/A **Application due:** **11/5/2023**	**National Institutes of Health, National Cancer Institute**	Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)	This Funding Opportunity Announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$250,000	5 years	dmitchum@mail.nih.gov	Dawn Mitchum
LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	mutema.nyankale@nih.gov	Mutema Nyankale
LOI due: 30 days before due date **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to invite research grant applications (R01) for the development and use of current and emerging molecular imaging methods to gain fundamental insights into cancer inflammation in vivo. The motivation for this initiative is that much of current imaging research into the role of inflammation in cancer is largely based on in vitro and ex vivo methods with limited utilization of imaging approaches that could lead to significant new insights relevant to dynamic cancer and inflammation interactions. Utilization of molecular imaging probes in pre-clinical and clinical investigations for precise temporal resolution at the molecular and cellular level are valuable approaches for identification and characterization of in vivo inflammatory cellular physiology in cancers and of molecular changes in response to treatment. This FOA encourages applications that focus on developing integrated imaging approaches to interrogate the role of inflammation in cancer through strong cross-field collaboration between cancer basic science researchers and imaging scientists. These collaborations are expected to advance science and understanding of cancer inflammation interactions.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are limited to less than $500K in direct costs per year and the requested amount in any year needs to reflect the actual needs of the proposed project.	5 years	woodwars@mail.nih.gov	Shane Woodward

LOI due: N/A **Application due:** **Cycle III: 10/12/2023**	**National Institutes of Health, National Cancer Institute**	NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)	The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.	Any candidate who meets the eligibility and possesses the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Candidates for the K08 award must have a clinical doctoral degree. Such degrees include, but are not limited to: MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), and DVM. Individuals with the PhD or other doctoral degree in clinical disciplines such as clinical psychology, nursing, clinical genetics, speech-language pathology, audiology or rehabilitation are also eligible. Individuals holding the PhD in a non-clinical discipline who are certified to perform clinical duties should contact the National Cancer Institute (NCI) concerning their eligibility for a K08 award.	Award budgets are composed of salary and other program-related expenses	5 years	hines@mail.nih.gov	Sean Hine
LOI due: N/A **Application due:** **Cycle III: 10/12/2023**	**National Institutes of Health, National Cancer Institute**	NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed)	The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree or a health professional doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. This NCI-sponsored K08 award is specifically designed to enhance the diversity in the NCI-funded cancer research workforce by supporting eligible clinical scientists from diverse backgrounds, including groups that have been shown to be nationally underrepresented in health-related sciences and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.	Any candidate who meets the eligibility and possesses the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Candidates for the K08 award must have a clinical doctoral degree. Such degrees include, but are not limited to: MD, DO, DDS, DMD, OD, DC, PharmD, ND (Doctor of Naturopathy), and DVM. Individuals with the PhD or other doctoral degree in clinical disciplines such as clinical psychology, nursing, clinical genetics, speech-language pathology, audiology or rehabilitation are also eligible. Individuals holding the PhD in a non-clinical discipline who are certified to perform clinical duties should contact the National Cancer Institute (NCI) concerning their eligibility for a K08 award.	Award budgets are composed of salary and other program-related expenses	5 years	hines@mail.nih.gov	Sean Hine
LOI due: N/A **Application due:** **Cycle III: 10/12/2023**	**National Institutes of Health, National Cancer Institute**	NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)	The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.	Any candidate who meets the eligibility and possesses the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	3 years	hines@mail.nih.gov	Sean Hine
LOI due: 30 days before due date **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)	Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)	**The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this FOA, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.**	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$450,000	5 years	nyankalem@mail.nih.gov	Mutema Nyankale
LOI due: 30 days before due date **Application due:** **9/29/2023**	**National Institutes of Health, National Cancer Institute**	Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional)	The purpose of this Funding Opportunity Announcement (FOA) is to support studies that aim to better understand and/or address survivorship needs for individuals living with likely incurable cancer. This group is heterogenous in terms of cancer type, treatments received, prognosis, and outcomes. Specifically, this RFA is intended to solicit applications proposing 1) observational studies to understand the trajectory of physical and psychological symptoms, patterns of care, and unmet needs; and/or 2) the development and testing of interventions to improve the delivery of comprehensive survivorship care in this group of cancer survivors.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$500,000	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A **Application due:** **Cycle III: 10/5/2023**	**National Institutes of Health, National Cancer Institute**	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study effects of different types of radiation used in radionuclide based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells and the tumor microenvironment.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$500,000	5 years	woodwars@mail.nih.gov	Shane Woodward

LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed)	This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) and who has at least 2 years of postdoctoral cancer research training, but, no more than a total of 8 years of mentored, non-independent training experience after the terminal research doctorate or clinical degree is invited to work with his/her organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	3 years	amy.bartosch@nih.gov	Amy Bartosch
LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)	This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) and who has at least 2 years of postdoctoral cancer research training, but, no more than a total of 8 years of mentored, non-independent training experience after the terminal research doctorate or clinical degree is invited to work with his/her organization to develop an application for support.	Award budgets are composed of salary and other program-related expenses	3 years	amy.bartosch@nih.gov	Amy Bartosch
LOI due: N/A Application due: Cycle III: 10/12/2023	**National Institutes of Health, National Cancer Institute**	The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)	This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.	**Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) and who has at least 2 years of postdoctoral cancer research training, but, no more than a total of 8 years of mentored, non-independent training experience after the terminal research doctorate or clinical degree is invited to work with his/her organization to develop an application for support.**	Award budgets are composed of salary and other program-related expenses	3 years	amy.bartosch@nih.gov	Amy Bartosch
LOI due: N/A Application due: Cycle III: 11/17/2023	**National Institutes of Health, National Cancer Institute**	Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)	**This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature experimental nanomedicines designed for highly relevant cancer clinical objectives with a strong potential to improve cancer treatment effectiveness. It is expected that improvement of treatment effectiveness will occur due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.**	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$475,000	4 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, National Cancer Institute, National Institute of Dental and Craniofacial Research**	Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)	This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflerct the actual needs of the proposed project	5 years	hines@mail.nih.gov	Sean Hine
LOI due: N/A Application due: Cycle III: 10/5/2023	**National Institutes of Health, National Human Genoma Research Institute**	Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed)	The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research that develops innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$500,000	5 years	natalie.linear@nih.gov	Natalie Linear
LOI due: 30 days before due date Application due: 10/11/2023	**National Institutes of Health, National Institute of Allergy and Infectious Diseases**	Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed)	**The purpose of this funding opportunity is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies**	**Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.**	$2M	5 years	robert.unfer@nih.gov	Robert Unfer
LOI due: N/A Application due: Cycle III: 10/16/2023	**National Institutes of Health, National Institute of Allergy and Infectious Diseases**	Limited Competition: Small Research Grant Program for NIAID K01/K08/K23 Recipients (R03 Clinical Trial Not Allowed)	The National Institute of Allergy and Infectious Diseases (NIAID) announces a program that provides NIAID-supported K01, K08, and K23 recipients with the opportunity to apply for Small Research Grant (R03) support at some point during the final two years of their K award. Through the use of this mechanism, NIAID seeks to enhance the capability of its K01, K08, and K23 award recipients to conduct research as they complete their transition to fully independent investigator status (e.g., R01 support). The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$50,000/year	2 years	tamia.powell@nih.gov	Tamia Powell

LOI due: 30 days before due date **Application due: 10/11/2023**	**National Institutes of Health, National Institute of Allergy and Infectious Diseases**	Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)	The objective of this funding opportunity is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs) It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	adevine@niaid.nih.gov	
LOI due: N/A **Application due: Cycle III: 10/5/2023**	**National Institutes of Health, National Institute of Environmental Health Sciences, National Institute on Minority Health and Health Disparities**	Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)	This funding opportunity encourages multidisciplinary projects to investigate the potential health risks of environmental exposures of concern to a community and to develop and implement an environmental public health action plan based on research findings.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	$500,000	5 years	jenny.greer@nih.gov	Jenny Greer
LOI due: N/A **Application due: Cycle III: 10/5/2023**	**National Institutes of Health, National Institute on Aging**	Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)	This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the needs of the proposed project	5 years	properr@mail.nih.gov	Richard Proper
LOI due: 30 days before due date Application due: 10/23/2023	**National Institutes of Health, National Institute on Aging**	Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required)	This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention's principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Women and individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	ryan.blakeney@nih.gov	Ryan Blakeney
LOI Due: 9/23/2023 **Application due: 10/23/2023**	**National Institutes of Health, National Institute on Aging**	Measuring Financial Hardship Among People and Families Living with AD/ADRD (R01 Clinical Trial Not Allowed)	The purpose of this initiative is to develop measures of the financial hardship associated with Alzheimer's disease (AD) and AD-related dementias (ADRD) that are responsive to the dyadic and family-level financial management arrangements that are common as AD/ADRD progresses. This notice of funding opportunity (NOFO) invites research to support the development of measures of financial hardship for persons living with AD/ADRD and their partners, families, or caregivers to facilitate research on financial health - a key social determinant of health - and health- related quality of life among older adults with AD/ADRD	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	$500,000	5 years	ryan.blakeney@nih.gov	Ryan Blakeney
LOI due: N/A **Application due: Cycle III: 10/5/2023**	**National Institutes of Health, National Institute on Aging**	National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)	The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD) and the Office of HIV and AIDS Malignancies (OHAM, Office of the Director). Applicants are strongly encouraged to consult the NCI DCTD website and/or the OHAM website to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial and provide specific clinical trial information as described in this FOA.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	$499,999	5 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: N/A **Application due: Cycle III: 10/12/2023**	**National Institutes of Health, National Institute on Aging**	NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)	The objective of the NIA Academic Leadership Career Award (K07) is to provide support for senior investigators who have the expertise and leadership skills to enhance aging and geriatric research capacity within their academic institution.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Award budgets are composed of salary and other program-related expenses	5 years	lafferttl@nia.nih.gov	Traci Lafferty
LOI due: N/A **Application due: 10/12/2023**	**National Institutes of Health, National Institute on Aging**	NIA Advanced Postdoctoral Career Transition Awards to Promote Diversity in Translational Research for AD/ADRD (K99/R00 Clinical Trial Not Allowed)	The purpose of this Funding Opportunity Announcement (FOA) is to promote diversity in the translational research workforce for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This pathway to independence award will emphasize the development of skills in data science and drug discovery, and their application to various aspects of AD/ADRD research (from populations studies to research that can lead to new treatments and diagnostics, including all aspects of behavioral and social research). This award will support early career investigators from diverse backgrounds to gain critical translational skills in data science and drug discovery and transition to research independence. The long-term goal of this program is to develop a diverse translational research workforce that can effectively participate in and/or lead a team-science, precision medicine approach to studies of AD/ADRD treatment, prevention, early detection, and disease management and care.	Any candidate with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. K99/R00 applicants must have no more than 4 years of postdoctoral research experience as of the relevant application due date regardless of whether it is a new or resubmission application. Individuals must be in mentored, postdoctoral training positions to be eligible to apply to the K99/R00 program. If an applicant achieves independence (i.e., any faculty or non-mentored research position) before a K99 award is made, neither the K99 award, nor the R00 award, will be issued.	Award budgets are composed of salary and other program-related expenses	5 years	perezj@mail.nih.gov	Jessi Perez

LOI due: N/A **Application due:** **Cycle III: 10/12/2023**	**National Institutes of Health, National Institute on Aging**	NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)	The purpose of the NIA Career Transition Award (CTA) is to facilitate the transition of mentored researchers to tenure-track faculty positions conducting research that advances the mission of NIA. This award will provide three years of protected time through salary and research support to conduct biomedical research at an extramural sponsoring institution/organization to which the individual has been recruited, been offered, and has accepted a tenure-track full-time assistant professor position (or equivalent).	knowledge, and resources necessary to carry out the proposed research as the Program Director/Principal Investigator (PD/PI) is invited to work with his/her mentor and organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applications will only be considered from candidates that have earned a terminal research doctorate or clinical degree (including PhD, MD, DO, DC, ND, DDS, DMD, DMV, ScD, DNS, PharmD, or equivalent) or a combined research doctorate/clinical degrees. At least 2 years of postdoctoral or equivalent training in areas relevant to the mission of NIA is required. Candidates with a prior individual career development award or research project grant from the Federal Government are not eligible (with the exception of R03 or R21). Clinical faculty members who do not hold an independent research faculty positions may be eligible for the K22 award but are encouraged to obtain confirmation of their eligibility before they begin to prepare their applications. Individuals are eligible for a K22 award if they have been, or currently are, the PD/PI of an NIH R03 or R21	Award budgets are composed of salary and other program-related expenses	3 years	jessi.perez@nih.gov	Jessi Perez
LOI due: 9/23/2023 **Application due:** **10/23/2023**	**National Institutes of Health, National Institute on Aging**	Significance of Clonal Hematopoiesis (CH) in Aging Humans (R01 Clinical Trial Not Allowed)	The purpose of this funding opportunity is to stimulate the use of existing biospecimens and datasets which will increase our understanding of the clinical significance of clonal hematopoiesis mutations, their causality, directionality, relationships with different human aging phenotypes and underlying biological mechanisms.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) PD(s)/PI(s)) is invited to work with their organization to develop an application for support.	$1M	5 years	nragahvachari@mail.nih.gov	Nalini Raghavachari
LOI due: N/A **Application due:** **8/30/2023**	**National Institutes of Health, National Institute on Drug Abuse**	Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)	The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	wellse2@nida.nih.gov	Ericka Wells
LOI due: 30 days before due date **Application due:** **11/14/2023**	**National Institutes of Health, National Institute on Drug Abuse**	NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)	This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and ethnic minority populations in substance use, addiction, and related health consequences, including HIV.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project	5 years	kwesi.wright@nih.gov	Kwesi Wright
LOI due: 30 days before due date **Application due:** **11/17/2023**	**National Institutes of Health, National Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases**	Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)	This funding announcement will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the effects of an overdose and the observed toxicities caused by acute Ultra-Potent Synthetic (UPS) opioid exposure.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	$300,000	3 years	ericka.wells@nih.gov	Ericka Wells
LOI due: 9/29/2023 **Application due:** **10/31/2023**	**American Cancer Society/Stephenson Cancer Center**	Institutional Research Grant	Provide small pilot research funding to beginning investigators who have not yet achieved independent funding at the national level	Full time Assistant Professors within six years of their first independent faculty appointment and with no active peer-reviewed research funding from national funding agencies	$60,000	1 year		
LOI due: 10/02/2023 **Application due:** **11/02/2023**	**National Institutes of Health, National Institute on Aging**	Development and Validation of Harmonized Methodologies to Measure NAD+ and Related Metabolites in Clinical Trials (U01 Clinical Trial Required)	This notice of funding opportunity (NOFO) invites applications to develop and validate the standardized protocols for measuring nicotinamide adenine dinucleotide (NAD+) and related metabolites levels in humans, including sample collection and storage, assays' calibration, and standardization of measurements across different types of samples, such as plasma, tissue, or serum extracts, and validation of these protocols	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	Application budgets are not limited but need to reflect the acutal needs of the proposed project	5 years	laura.pone@nih.gov	Laura Pone
LOI due: 9/20/2023 **Application due:** **10/20/2023**	**National Institutes of Health, National Institute on Aging**	Primary Care-Based Screening Tool and Intervention Development for the Detection and Prevention of Abuse and Neglect in Older and Vulnerable Adults With, or at Risk for, Mild Cognitive Impairment and AD/ADRD (R61/R33 Clinical Trial Required)	The purpose of this Notice of Funding Opportunity (NOFO) is to support research that can lead to the development of primary care-based screening tools and early interventions to detect and prevent abuse and neglect (hereafter referred to as "AN") in older and vulnerable adults living with, or at risk for, mild cognitive impairment (MCI) and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). In the interest of supporting early-stage research conducted by interdisciplinary teams that can lead to the development of screening tools and behavioral interventions that can be successfully implemented in primary care settings with diverse patient populations, this NOFO invites five-year, R61/R33 phased award applications.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$750,000	5 years	ryan.blakeney@nih.gov	Ryan Blakeney
LOI due: 30 days before due date **Application due:** **9/25/2023**	**National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse**	Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)	The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$250,000	4 years	jfox@mail.nih.gov	Judy Fox

LOI due: 30 days before due date **Application due: 11/15/2023**	**National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases**	Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)	The purpose of this notice of funding opportunity is to invite Institutional Network Awards (U2C-TL1) to cultivate a highly integrated cohort of trainees and early career investigators and to develop career development resources to accelerate kidney, urologic, and hematologic research. To maximize integration and promote a true trainee community, Institutions are invited to submit a single, unified U2C-TL1 application to engage, recruit, prepare, and sustain the next generation of scientists able to contribute to advancing research in kidney, urology, and hematology. Applications representing multiple institutions within a single metropolitan area are strongly encouraged (see Section III.3). Successful awardees are expected to relinquish all active T32s supported by the NIDDK, Division of Kidney, Urologic, and Hematologic Diseases (KUH) at the time of the U2C-TL1 award.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	The total costs of the Administrative Core, Professional Development Core, and Networking Core (U2C) should not exceed 70% of the total cost of the NRSA Training Core (TL1). In other words, the total costs of the U2C divided by the total costs of the TL1 should not exceed 0.70.	5 years	ajosea@mail.nih.gov	Aricia Ajose
LOI due: N/A **Application due: 10/5/2023 2/05/2024**	**National Institutes of Health et al**	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) (nih.gov)	Through this Notice of Funding Opportunity, the National Cancer Institute along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$350,000	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A **Application due: 10/16/2023 2/16/2024**	**National Institutes of Health et al**	Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$275,000	2 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 60 days before due date **Application due: 12/06/2023**	**National Institutes of Health et al**	Public Health Communication Messaging about the Continuum of Risk for Tobacco Products (U01 Clinical Trial Required)	The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications for a Research Project (U01) that will utilize health communication research to better understand the impact that messaging about the continuum of risk for tobacco products may have on various segments of the population. The NIH and the FDA have formed an interagency partnership to foster research relevant to tobacco regulatory science within the framework of the Family Smoking Prevention and Tobacco Control Act (FSPTCA). The award under this NOFO will be administered by NIH using designated funds through an interdepartmental delegation of authority (IDDA) from the FDA Center for Tobacco Products (CTP) for tobacco regulatory science mandated by the FSPTCA.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$2.5M	4 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A **Application due: 11/03/2023 5/3/2024**	**National Institutes of Health, National Cancer Institute**	Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)	Through this Notice of Funding Opportunity (NOFO) entitled "Innovative Research in Cancer Nanotechnology (IRCN)", the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address overcoming major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets *in vivo* and/or characterization of detection and diagnostic devices and sensors *in vitro*. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is outside of scope of this NOFO.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$475,000	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 9/29/2023 **Application due: 10/31/2023**	**National Institutes of Health, National Institute on Aging**	Health Equity and the Cost of Novel Treatments for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)	This notice of funding opportunity (NOFO) invites applications to address health equity, drug costs, and access to new therapeutics for people living with Alzheimer's disease (AD) and AD-related dementias (ADRD). Applicants must identify preferences for pharmacological treatment among racial and ethnic minorities living with AD/ADRD, assess whether cost barriers to pharmacological care exist for these groups, and quantify expenditures and health-related quality of life (HRQoL) among people interested in receiving novel drugs to treat AD/ADRD.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	For the R61 phase, the budget for direct costs may not exceed $200,000 per year. For the R33 phase, the budget for direct costs may not exceed $400,000 per year. Application budgets need to reflect the actual needs of the proposed project.	The maximum period of the combined R61/R33 phases is 5 years, with 1-2 years for the R61 phase and 3-4 years for the R33 phase. Funding of the R33 award will be determined by successful completion of the R61 milestones, program priorities, and availability of funds, as determined by NIH	jeni.smits@nih.gov	Jeni Smit

LOI due: 10/15/2023 Application due: 11/15/2023	**National Institutes of Health, National Cancer Institute**	Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed)	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to solicit applications for basic research projects investigating the molecular mechanisms by which fusion oncoproteins drive pediatric cancers. The overall goal of this solicitation and the companion NOFO, RFA-CA-23-037, is to form a new dynamic network of investigators that will use rigorous and collaborative efforts to advance our understanding of the mechanisms of action of fusion oncoproteins in pediatric cancers and to apply novel chemical strategies to accelerate innovative drug discovery and preclinical development of therapeutics for fusion oncoprotein-driven childhood cancers. This NOFO solicits U01 applications for discrete research projects focused on molecular mechanisms by which fusion oncoproteins drive pediatric cancers with the goal of identifying key factors involved in oncogenesis which could serve as critical dependencies or potential targets for therapeutic intervention.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$325,000/year	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 10/15/2023 Application due: 11/15/2023	**National Institutes of Health, National Cancer Institute**	Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to create multidisciplinary research groups or partnerships for the discovery of pharmacological agents to treat fusion oncoprotein-driven childhood cancers. This NOFO will use the UM1 mechanism to fund Next Generation Chemistry (NGC) Centers with interdisciplinary teams focusing on innovative medicinal chemistry, chemical biology and chemoproteomic approaches to target fusion oncoprotein-driven cancers. The goal of this program is to accelerate innovative drug discovery focused on developing small molecules to effectively disrupt fusion oncoproteins through mechanisms including, but not limited to, inhibiting activities of fusion oncoproteins, blocking critical fusion oncoprotein interactions, modulating coding and/or noncoding RNAs required for fusion protein oncogenesis, and selectively degrading fusion proteins and/or proteins representing critical fusion oncoprotein dependencies. The NCI encourages applications to advance the discovery, preclinical development, and proof of concept testing of new, rationally designed candidate agents to treat fusion-derived childhood cancers. Funding priority will be given to applications that focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted therapeutic agents. Applications focused on pediatric solid tumors and brain tumors are particularly encouraged. Small molecules are defined here as chemically synthesized drug-like compounds with molecular weights <2000	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$1.5M/year	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 01/01/2024 Application due: 02/01/2024	**National Institutes of Health et al**	HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)	The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This NOFO is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$400,000	5 years	lennin.greenwood@nih.gov	Lennin Greenwood
LOI due: 01/01/2024 Application due: 02/01/2024	**National Institutes of Health et al**	HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)	The purpose of this notice of funding opportunity (NOFO) is to support research focusing on the identification of druggable new targets and the discovery of optimizable probes for the development of safe and efficacious medications to prevent and treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This NOFO is part of the NIH Helping to End Addiction Long-term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$275,000	2 years	lennin.greenwood@nih.gov	Lennin Greenwood
LOI due: 09/11/2023 Application due: 10/11/2023	**National Institutes of Health; National Heart, Lung and Blood Institute**	The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)	The purpose of this Notice of Funding Opportunity (NOFO) is to elucidate the contribution of sleep deficiency and circadian disruption to metabolic and cardiovascular pathobiology, disease trajectory, and treatment response in individuals living with Type 1 Diabetes (T1D). The NOFO will support clinically relevant, mechanism focused research on the interface between sleep, circadian rhythms biology, T1D and cardiovascular disease. Multi-disciplinary teams bridging sleep/circadian, diabetes, and cardiovascular research are encouraged. Proposed research should be relevant to the ultimate goal of applying sleep and circadian strategies to improve treatment and outcomes in individuals with T1D, and to mitigate related cardiovascular complications. Observational studies, epidemiology, efficacy trials and basic animal research will not be responsive to this NOFO.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$420,000	5 years	kim.hall@nih.gov	Kim Hall
LOI due: 09/11/2023 Application due: 10/11/2023	**National Institutes of Health; National Heart, Lung and Blood Institute**	The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R34 Clinical Trial Optional)	This Notice of Funding Opportunity (NOFO) will support preliminary studies aimed at obtaining information necessary to guide the design of a full randomized control trial to test whether sleep and circadian targeted interventions improve the clinical course and treatment outcomes in individuals with Type 1 Diabetes (T1D). Applications should focus on pilot studies to inform practical and potentially sustainable strategies to improve processes of care and cardiometabolic health outcomes in individuals with T1D. The scope of research for this NOFO includes a range of feasibility metrics (e.g., optimizing recruitment, retention, randomization); intervention logistics (e.g., determine independent variable(s), dose-response, duration); study design/statistical considerations (e.g., determination of effect size, sample size, and statistical power; inclusion/exclusion criteria, control variables); adherence outcomes (measures of patient acceptance of, satisfaction with, and adherence to treatment); assessment of intermediate markers of the intervention (e.g. glycemic control, vascular dysfunction, inflammation, and/or neuroendocrine and metabolic function); and selection of primary and/or secondary outcome(s) measures. Ultimately, results from these pilot studies will be used to develop a well-powered, evidence-based definitive clinical trial that could improve clinical care and cardiometabolic outcomes in individuals with T1D and to inform guidelines for this patient population. Transdisciplinary investigative teams including relevant expertise in sleep/circadian, T1D and cardiovascular research, as well as needed expertise in clinical	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$225,000	2 years	kim.hall@nih.gov	Kim Hall

LOI due: 30 days before due date Application due: 10/05/2023 02/05/2024	**National Institutes of Health, National Cancer Institute**	Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)	Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	Application budgets are not limited but need to reflect the actual needs of the proposed project.	3 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: N/A Application due: 10/05/2023 02/05/2024	**National Institutes of Health**	Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)	This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one's response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. Program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	Application budgets are not limited but need to reflect the actual needs of the proposed project.	5 years	woodwars@mail.nih.gov	Shane Woodward
LOI due: 10/03/2023 Application due: 11/03/2023	**National Institutes of Health, National Institute on Aging**	Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD (R01 Clinical Trial Not Allowed)	This Notice of Funding Opportunity (NOFO) invites innovative R01 applications that explore how structural, community, and interpersonal mechanisms operate over the life course among middle- and older-aged racial and/or ethnic subgroups considered to be a minority in the US (see OMB Directive 15) to shape health outcomes, and any resulting in health disparities. This NOFO also invites innovative applications that explore data needs and methods when studying the effect of immigration on life-course health, including Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD).	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$500,000	5 years	ryan.blakeney@nih.gov	Ryan Blakeney
LOI due: 10/03/2023 Application due: 11/03/2023	**National Institutes of Health, National Institute on Aging**	Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD (R01 Clinical Trial Not Allowed)	This Notice of Funding Opportunity (NOFO) invites innovative R01 applications that explore how structural, community, and interpersonal mechanisms operate over the life course among middle- and older-aged racial and/or ethnic subgroups considered to be a minority in the US (see OMB Directive 15) to shape health outcomes, and any resulting in health disparities. This NOFO also invites innovative applications that explore data needs and methods when studying the effect of immigration on life-course health, including Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD).	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$200,000/year	2 years	ryan.blakeney@nih.gov	Ryan Blakeney
LOI due: 10/03/2023 Application due: 11/03/2023	**National Institutes of Health, National Institute on Aging**	Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional)	The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that investigate the neural and/or non-neural mechanisms that underlie the association between gait and cognition in aging and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). Elucidating these mechanisms would help inform the potential use of changes in gait as an early biomarker of AD/ADRD or inform the design of early interventions for AD/ADRD. To achieve this goal, it is necessary to facilitate a team science approach by bringing experts together from various relevant disciplines, such as gerontology, neurology, neuropsychology, neurophysiology, neuroscience, neuroimaging, exercise physiology, and physical therapy.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$700,000	5 years	kathleen.moy@nih.gov	Kathleen Moy
LOI due: 10/03/2023 Application due: 11/03/2023	**National Institutes of Health, National Institute on Aging**	Elucidating Variability of Physiologic and Functional Responses to Exercise Training in Older Adults (R01 Clinical Trial Required)	The National Institute on Aging (NIA) invites R01 applications that propose human studies to better understand factors underlying response variability to exercise training in older adults through this Notice of Funding Opportunity (NOFO). This NOFO encourages studies that identify systemic modulators, biomarkers, and other potential mechanisms underlying exercise variation in outcomes that are clinically relevant for older adults. Additionally, this NOFO encourages transdisciplinary studies utilizing innovative design methods and analytical approaches combined with clinical phenotyping to disentangle the complicated relationships between endogenous and exogenous factors that drive response variation to exercise. Elucidating factors and mechanisms that underlie variations in exercise response, and the extent to which these factors are modifiable, may enable more precise and efficacious exercise prescriptions to optimize the clinical efficacy of exercise training in older adults.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$1M	5 years	laura.pone@nih.gov	Laura Pone
LOI due: N/A Application due: 11/07/2023	**National Institutes of Health et al**	HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional)	This notice of funding opportunity (NOFO) seeks to support research aimed at holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on 'Whole Person Health' and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use / misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$650,000	5 years	hines@mail.nih.gov	Sean Hine

LOI due: N/A Application due: 02/05/2024	**National Institutes of Health**	Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)	This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	Application budgets are not limited but need to reflect the actual needs of the proposed project.	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 10/03/2023 Application due: 11/03/2023	**National Institutes of Health, National Institute on Aging**	Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional)	This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer's disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	Application budgets are not limited but need to reflect the actual needs of the proposed project.	4 years	philip.smith2@nih.gov	Philip Smith
LOI due: N/A Application due: 02/05/2024	**National Institutes of Health et al**	Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)	The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this NOFO seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	Application budgets are not limited but need to reflect the actual needs of the proposed project.	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A Application due: 10/05/2023 02/05/2024	**National Institutes of Health, National Cancer Institute**	Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)	The NCI, through this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$499,000	5 years	amy.bartosch@nih.gov	Amy Bartosch
LOI due: 30 days before due date Application due: 11/29/2023	**National Institutes of Health, et al**	Understanding and Mitigating Health Disparities experienced by People with Disabilities caused by Ableism (R01 Clinical Trial Optional)	The goal of this NOFO is to encourage research to understand the impact of ableism on health outcomes. Research on the underlying mechanisms by which ableism adversely influences the health of persons with disabilities (PWD), as well as developing and/or testing interventions at a community or health systems level to mitigate adverse health effects of ableism are high priority.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support	$499,000	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: 10/20/2023 Application due: 11/20/2023	**National Institutes of Health, et al**	HEAL Initiative: HEAL KIDS (Knowledge, Innovation and Discovery Studies) Pain Program Resource and Data Center (U24 Clinical Trial Not Allowed)	As part of the NIH's Helping to End Addiction Long-term (HEAL) Initiative, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and participating NIH Institutes and Centers invite applications for a single HEAL KIDS Pain Resource and Data Center (RDC) to provide the following: leadership in data collection and management, data curation, data harmonization, and the development of data standards; administrative and logistical support including oversight of NIH HEAL-related requirements; and coordination of shared research-related resources all for the HEAL KIDS Pain research activities. This Notice of Funding Opportunity (NOFO) runs in parallel with a companion NOFO (RFA-HD-24-011) that invites applications to support innovative, multi-site, large-scale clinical trials to advance the understanding, assessment, measurement, treatment, and prevention of acute pain in infants, children, and adolescents, including those with disabilities and/or experiencing health disparities.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. The PD(s)/PI(s) (or Multi-PDs/PIs) should be an experienced investigator and capable of providing both administrative and scientific leadership to the development and implementation of the proposed activities. The PD(s)/PI(s) should have a strong track record coordinating and administrating large and collaborative projects and datasets, and demonstrated experience in effectively communicating, messaging, and disseminating various resources and information to stakeholders. Experience and/or expertise in large scale, multisite pediatric clinical trials and the unique aspects of conducting research in the pediatric population is preferred.	$600,000	6 years	kathleen.moy@nih.gov	Kathleen Moy
LOI due: N/A Application due: 12/08/2023 04/08/2024	**National Institutes of Health et al**	Ruth L. Kirschstein National Research Service Award (NRSA) Individual Senior Fellowship (Parent F33)	The National Institutes of Health (NIH) awards senior individual research training fellowships to experienced scientists who wish to make major changes in the direction of their research careers or who wish to broaden their scientific background by acquiring new research capabilities as independent investigators in research fields relevant to the missions of participating NIH Institutes and Centers. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. Senior fellows must have a doctoral degree and at least 7 subsequent years of relevant research or professional experience and must have established an independent research career.	Award budgets are composed of stipends, tuition and fees, and institutional allowance	Individuals may receive up to 5 years of aggregate Kirschstein-NRSA support at the predoctoral level (up to 6 years for dual degree training, e.g., MD/PhD), and up to 3 years of aggregate Kirschstein-NRSA support at the postdoctoral level, including any combination of support from institutional training grants (e.g., T32) and an individual fellowship award. Senior fellowship (F33) support is typically requested for 2 years or less.		

LOI due: N/A **Application due:** **12/08/2023** **04/08/2024**	**National Institutes of Health**	Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose?dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	Application budgets are not limited but need to reflect the actual needs of the proposed project.	5 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A **Application due:** **12/08/2023** **04/08/2024**	**National Institutes of Health**	Mechanisms the Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)	Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer.	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	$275,000	2 years	wolfreyc@mail.nih.gov	Crystal Wolfrey
LOI due: N/A **Application due:** **10/19/2023**	**American Society for Clinical Oncology**	Career Development Award	The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed. Applications in all areas of cancer research are accepted from U.S. and international applicants.	• Be a physician (MD, DO of international equivalent) working in any country. • Be in the first to third year of a full-time primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission. Application must be submitted before the applicant has had three full years as faculty. Faculty appointment may begin with the entry-level faculty position within the applicant's institution (i.e., Instructor/Lecturer, Assistant Professor, Assistant Member). • Have a valid, active medical license in the country where the research will be conducted at the time of application. • Have completed productive postdoctoral research and demonstrated the ability to undertake independent investigator-initiated clinical research. • Be an ASCO member or have submitted a membership application with the grant application. • Be able to commit at least 50% of full-time effort in research (applies to total research, not just the proposed project) during the award period. • Have a mentor from the sponsoring institution who must provide a letter of support. If the mentor is not an ASCO Member, a supporting letter from an ASCO Member from the sponsoring institution must be included. • Be up-to-date and in compliance with	$200,000			
Young Investigator Award Eligibility Checklist: 10/20/2023 **Application due:** 11/3/2023	Melanoma Research Alliance Foundation	General RFP - Young Investigator	The Melanoma Research Alliance (MRA) announces a Request for Proposals (RFP) soliciting high-impact pre-clinical, translational, and early clinical research from scientists and clinicians around the world. The RFP calls for ideas that have the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment.	Applicants must be within four years of their first independent, full time academic faculty appointment at the time of application at the level of Assistant Professor (or equivalent position). Fellows or others who are in training are not eligible to apply.	$225,000			
LOI due: N/A **Application due:** **10/19/2023**	**American Association for Cancer Research**	Clinical Oncology Research (CORE) Training	The AACR Clinical Oncology Research (CORE) Training Fellowships Program is designed to provide an industry-academic clinical practicum with a unique opportunity for academic clinicians to train in drug development. Each fellowship provides $100,000 over one year for the fellow to work on site at the facility of one of the AACR's pharmaceutical industry partners. This fellowship is designed for early-career clinical scientists who hold a medical degree (MD, DO, or MD/PhD) and are interested in acquiring the knowledge and skills related to drug development from the perspective of the pharmaceutical industry. The fellow will gain real-world experience in drug development, including clinical research, clinical trial design, and data analysis.	• Have a medical degree (including MD, DO, or MD/PhD) in a related field, and not currently be a candidate for a further doctoral degree. • Have enrolled in an accredited hematology/oncology fellowship program at an academic, medical, or research institution within the United States • Not be employees or subcontractors of a U.S. government entity or for-profit private industry or be clinical fellows applying from a U.S. government laboratory (e.g., NIH, CDC, FDA, etc.). · Individuals from racial and ethnic groups that have been shown by the National Science Foundation to be underrepresented in health-related sciences on a national basis · Individuals with disabilities, who are defined as those with a physical impairment that substantially limits one or more major life activities · Individuals from disadvantaged backgrounds	$100,000			
LOI due: 10/16/2023 **Application due:** **01/08/2024**	**American Association for Cancer Research**	Lustgarten-Swim Across America Pancreatic 2023	The Lustgarten Foundation-Swim Across America-AACR Pancreatic Cancer Early Detection Research Grant represents a joint effort to support innovative research to advance efforts towards the early detection and interception of pancreatic cancer. Applications from investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to pancreatic cancer research are especially encouraged.	Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Postdoctoral or clinical research fellows or the equivalent who are working under the auspices of a scientific mentor are not eligible to apply. Qualified fellows are invited to apply for an AACR Fellowship.	$300,000	3 years	grants@aacr.org	
LOI due: N/A **Application due:** **10/19/2023**	**The Asco Foundation**	Career Development Award	The Career Development Award (CDA) provides research funding to clinical investigators, who have received their initial faculty appointment, as they work to establish an independent clinical cancer research program. This is a mentored award and the research project is conducted under the guidance of a scientific mentor.	Applicants must be a physician; in the first to fourth year. of a full-time primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission. Application must be submitted before the applicant has had four full years as faculty. Faculty appointment may begin with the entry-level faculty position within the applicant's institution (i.e., Instructor/Lecturer, Assistant Professor, Assistant Member).	$200,000	3 years		
LOI due: 10/20/2023 **Application due:** **01/19/2024**	**Leukemia & Lymphoma Society**	Translational Research Program	The Translational Research Program (TRP) was formed to enhance the transfer of basic research findings to clinical usefulness. Applications are sought that propose novel approaches to the prevention, diagnosis, or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular, or integrated systems findings and be conceptually innovative.	Applicant must hold a PhD, MD, DVM or equivalent degree	$750,000	3 years	researchprograms@lls.org	